Ph 2 Study of the Safety and Efficacy of Three HU6 Dose Levels and Placebo in Nonalcoholic Steatohepatitis
Status:
Recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
This is a phase 2 randomized, double-blind, placebo-controlled parallel group study of 3 dose
levels of HU6 in subjects with nonalcoholic steatohepatitis (NASH). Six months (26 weeks) of
dosing is planned, and subjects will be followed for safety, efficacy, pharmacodynamics (PD),
and pharmacokinetics (PK) during this time. The end-of-study visit will take place
approximately 4 weeks after the last dose of the study drug (Week 30).